NLS Historical Income Statement
| NLSPW Stock | USD 0.01 0 11.11% |
Historical analysis of NLS Pharmaceutics income statement accounts such as Selling General Administrative of 6.2 M can show how well NLS Pharmaceutics AG performed in making a profits. Evaluating NLS Pharmaceutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of NLS Pharmaceutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining NLS Pharmaceutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NLS Pharmaceutics is a good buy for the upcoming year.
NLS |
About NLS Income Statement Analysis
NLS Pharmaceutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to NLS Pharmaceutics shareholders. The income statement also shows NLS investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
NLS Pharmaceutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of NLS Pharmaceutics. It is also known as NLS Pharmaceutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from NLS Pharmaceutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into NLS Pharmaceutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. At this time, NLS Pharmaceutics' Interest Income is fairly stable compared to the past year. Selling General Administrative is likely to climb to about 6.2 M in 2024, whereas Net Interest Income is likely to drop (152.4 K) in 2024.
NLS Pharmaceutics income statement Correlations
Click cells to compare fundamentals
NLS Pharmaceutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NLS Pharmaceutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | (819.7K) | (233.7K) | (68.1K) | (100.9K) | (145.2K) | (152.4K) | |
| Depreciation And Amortization | 4.2M | 2.3M | 10.1K | 11.4K | 10.3K | 9.8K | |
| Interest Expense | 819.7K | 233.7K | 68.1K | 100.9K | 145.2K | 137.9K | |
| Selling General Administrative | 3.3M | 2.2K | 5.9K | 6.5K | 5.9M | 6.2M | |
| Other Operating Expenses | 4.2M | 2.3M | 11.9M | 15.5M | 11.8M | 8.6M | |
| Operating Income | (4.2M) | (2.3M) | (11.9M) | (15.5M) | (11.8M) | (12.4M) | |
| Net Income From Continuing Ops | (5.4M) | (2.9M) | (11.9M) | (16.5M) | (12.2M) | (12.8M) | |
| Ebit | (8.4M) | (4.6M) | (11.9M) | (15.5M) | (11.8M) | (12.4M) | |
| Research Development | 1.7M | 99.6K | 5.9M | 9.0M | 5.9M | 4.5M | |
| Ebitda | (4.2M) | (2.3M) | (11.9M) | (15.5M) | (11.8M) | (12.4M) | |
| Total Operating Expenses | 4.2M | 2.3M | 11.9M | 15.5M | 11.8M | 8.6M | |
| Income Before Tax | (5.4M) | (2.9M) | (11.9M) | (16.5M) | (12.2M) | (12.8M) | |
| Total Other Income Expense Net | (1.3M) | (562.1K) | (85.5K) | (1.0M) | (365.0K) | (383.2K) | |
| Net Income | (5.4M) | (2.9M) | (11.9M) | (16.5M) | (12.2M) | (12.8M) | |
| Income Tax Expense | (4.2K) | (2.3K) | (226.5K) | 2.0 | 1.8 | 1.71 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.